cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Erasca Inc
1 own
1 watching
Current Price
$3.91
$0
(0%)
logo-eras
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
473.21M
52-Week High
52-Week High
12.8
52-Week Low
52-Week Low
3.6
Average Volume
Average Volume
0.58M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization473.21M
icon52-Week High12.8
icon52-Week Low3.6
iconAverage Volume0.58M
iconDividend Yield--
iconP/E Ratio--
What does the Erasca Inc do?
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Read More
How much money does Erasca Inc make?
News & Events about Erasca Inc.
Globe Newswire
23days ago
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 41st annual J...
Zolmax
1month ago
Erasca, Inc. (NASDAQ:ERAS Get Rating) Director Bihua Chen bought 307,692 shares of the firms stock in a transaction that occurred on Tuesday, December 13th. The stock was purchased at an average cost of $6.50 per share, with a total value of $1,999,998.00. Following the completion of the transaction...
Globe Newswire
1month ago
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support combination development BRAF Class 2 and 3 alterations have no approved targeted therapies and ...
Market News Video
1month ago
In trading on Monday, shares of Erasca Inc (ERAS) touched a new 52-week low of 4.34/share. Thats a 11.66 share price drop, or -72.88% decline from the 52-week high of 16.00 set back on 12/31/2021...
Globe Newswire
1month ago
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and ...
Frequently Asked Questions
Frequently Asked Questions
What is Erasca Inc share price today?
plus_minus_icon
Can Indians buy Erasca Inc shares?
plus_minus_icon
How can I buy Erasca Inc shares from India?
plus_minus_icon
Can Fractional shares of Erasca Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Erasca Inc stocks?
plus_minus_icon
What is today’s traded volume of Erasca Inc?
plus_minus_icon
What is today’s market capitalisation of Erasca Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Erasca Inc?
plus_minus_icon
What percentage is Erasca Inc down from its 52-Week High?
plus_minus_icon
What percentage is Erasca Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.91
$0
(0%)
logo-eras
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00